V. V. Padma, S. Saikia, B. Prajapati, Sankha Bhattacharya
{"title":"Risk assessment of Esophageal Cancer Prevalence in North East India","authors":"V. V. Padma, S. Saikia, B. Prajapati, Sankha Bhattacharya","doi":"10.2174/1573394719666230120115938","DOIUrl":null,"url":null,"abstract":"\n\nThe North East (NE) India region has a quite distinct gene pool with over 160 scheduled tribes and 400 other sub-tribal populations. This region is the fourth contributor to the gene pool of the Indian sub-continent, which has associations with Tibeto-Burman speakers and Austro-Asiatic speakers settled in East and NE-India with Asian ties.\n\n\n\nMethods\nLiterature search and studies have shown that in India, notwithstanding the lack of data on population coverage, there exists no such evidence for a decline in age-standardized mortality rates in cancer and the number of deaths mostly in individuals less than 70 years.\n\n\n\nAnalytical epidemiological studies using molecular markers are currently the need of NE-India for prognostication of cancers in this region, which are quite different from the rest of India, such as esophageal cancer, lung cancer in females, stomach cancer, and nasopharyngeal cancers. In addition, there is a dire need for translational research in NE-India, as for cancer survival, it is not always feasible to generalize the current international guidelines for cancer to the population of NE-India so that high survival rates are achieved just like the rest of India and high-income rich countries. Factors, such as difference in incidence rate, socioeconomic factors, tumor biology and availability of resource in this region, determine the survival rates.\n\n\n\nIn this review, various factors involved in the high cancer burden in this region are discussed, particularly focusing on the genetic basis.\n","PeriodicalId":43754,"journal":{"name":"Current Cancer Therapy Reviews","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2023-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cancer Therapy Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573394719666230120115938","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The North East (NE) India region has a quite distinct gene pool with over 160 scheduled tribes and 400 other sub-tribal populations. This region is the fourth contributor to the gene pool of the Indian sub-continent, which has associations with Tibeto-Burman speakers and Austro-Asiatic speakers settled in East and NE-India with Asian ties.
Methods
Literature search and studies have shown that in India, notwithstanding the lack of data on population coverage, there exists no such evidence for a decline in age-standardized mortality rates in cancer and the number of deaths mostly in individuals less than 70 years.
Analytical epidemiological studies using molecular markers are currently the need of NE-India for prognostication of cancers in this region, which are quite different from the rest of India, such as esophageal cancer, lung cancer in females, stomach cancer, and nasopharyngeal cancers. In addition, there is a dire need for translational research in NE-India, as for cancer survival, it is not always feasible to generalize the current international guidelines for cancer to the population of NE-India so that high survival rates are achieved just like the rest of India and high-income rich countries. Factors, such as difference in incidence rate, socioeconomic factors, tumor biology and availability of resource in this region, determine the survival rates.
In this review, various factors involved in the high cancer burden in this region are discussed, particularly focusing on the genetic basis.
期刊介绍:
Current Cancer Therapy Reviews publishes frontier reviews on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.